Cerus (CERS)

Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

Company profile

Ticker

CERS

Exchange

NASDAQ

Website

www.cerus.com

CEO

William Greenman

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Boston Scientific • Baxter International • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...

SEC CIK

0001020214

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Cerus Europe B.V. ...

IRS number

680262011

CERS stock data

1M 1Y 5Y

News

From Benzinga Pro

Class Of 1997: 25 Years Decades After Their IPOs, Where Are These Companies Now?

19 May 22

Delivering on a promise is a tough proposition, and to consistently deliver requires excellence on all fronts.

Cerus Q1 EPS $(0.07) Beats $(0.09) Estimate, Sales $43.00M Beat $38.98M Estimate

5 May 22

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 30 percent increase over losses of $(0.10) per share from the same

Earnings Scheduled For May 5, 2022

5 May 22

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Cerus Corp. Reports New Manufacturing, Supply Deal With Fresenius Kabi For INTERCEPT Blood System Sets, No Terms Disclosed

3 May 22

Cerus Corporation Announces Multi-Year Contract For The INTERCEPT Blood System For Platelets With The American Red Cross; No Financial Terms Disclosed

25 Apr 22

Press releases

From Benzinga Pro

Cerus Corporation Celebrates World Blood Donor Day 2022

14 Jun 22

Cerus Corporation (NASDAQ:CERS) is proud to announce its celebration of World Blood Donor Day 2022. For over 15 years, World Blood Donor Day has helped served as an annual event to raise awareness of the crucial

Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range

5 May 22

Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S. Total Revenue of $43.0 Million Grew 46% YoY in the First Quarter Product Revenue of $37.4 Million Grew 60% YoY in the

Calendar

4 May 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart CERS financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	40.38M	40.38M	40.38M	40.38M	40.38M	40.38M
Cash burn (monthly)	3.56M	1.62M	4.07M	4.08M	7.15M	3.16M
Cash used (since last report)	10.22M	4.65M	11.7M	11.71M	20.56M	9.08M
Cash remaining	30.15M	35.72M	28.68M	28.66M	19.82M	31.29M
Runway (months of cash)	8.5	22.1	7.0	7.0	2.8	9.9

Beta Read what these cash burn values mean

Financial data from Cerus earnings reports.

Recent insider trades

CERS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Jun 22	Eric Bjerkholt	Common Stock	Grant	Acquire A	No	No	0	20,454	0	77,133
1 Jun 22	Eric Bjerkholt	Option Common Stock	Grant	Acquire A	No	No	4.84	39,866	192.95K	39,866
1 Jun 22	Moore Timothy L.	Common Stock	Grant	Acquire A	No	No	0	20,454	0	65,073
1 Jun 22	Moore Timothy L.	Option Common Stock	Grant	Acquire A	No	No	4.84	39,866	192.95K	39,866
1 Jun 22	Jami K Nachtsheim	Common Stock	Grant	Acquire A	No	No	0	20,454	0	66,362
1 Jun 22	Jami K Nachtsheim	Option Common Stock	Grant	Acquire A	No	No	4.84	39,866	192.95K	39,866
1 Jun 22	Schulze Gail	Common Stock	Grant	Acquire A	No	No	0	20,454	0	48,570
1 Jun 22	Schulze Gail	Option Common Stock	Grant	Acquire A	No	No	4.84	39,866	192.95K	39,866
1 Jun 22	Daniel N Swisher JR	Common Stock	Grant	Acquire A	No	No	0	20,454	0	113,808
1 Jun 22	Daniel N Swisher JR	Option Common Stock	Grant	Acquire A	No	No	4.84	39,866	192.95K	39,866

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

CERS institutional ownership history Ownership history

84.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	183	184	-0.5%
Opened positions	25	28	-10.7%
Closed positions	26	16	+62.5%
Increased positions	68	52	+30.8%
Reduced positions	49	66	-25.8%

13F shares	Current	Prev Q	Change
Total value	806.61M	1.01B	-20.2%
Total shares	148.92M	148.64M	+0.2%
Total puts	219.4K	324.2K	-32.3%
Total calls	392.8K	306.1K	+28.3%
Total put/call ratio	0.6	1.1	-47.3%

Largest owners	Shares	Value	Change
ARK Investment Management	16.21M	$89.01M	+2.9%
Baker Bros. Advisors	13.71M	$75.29M	0.0%
BLK Blackrock	12.16M	$66.78M	-0.4%
CMTDF Sumitomo Mitsui Trust	10.64M	$58.4M	-7.7%
Nikko Asset Management Americas	10.64M	$48.93M	-7.7%
Primecap Management	9.53M	$52.33M	-2.0%
Vanguard	9.04M	$49.64M	+2.5%
Wasatch Advisors	8.43M	$46.26M	+2.9%
STT State Street	4.63M	$25.45M	+4.3%
Senvest Management	4.19M	$22.99M	+14.8%

Largest transactions	Shares	Bought/sold	Change
CMTDF Sumitomo Mitsui Trust	10.64M	-892.41K	-7.7%
Nikko Asset Management Americas	10.64M	-892.41K	-7.7%
Natixis	745.4K	+745.4K	NEW
Tamarack Advisers	1.65M	+650K	+65.0%
Granahan Investment Management	0	-645.57K	EXIT
Kennedy Capital Management	1.41M	-637.92K	-31.2%
Senvest Management	4.19M	+539.6K	+14.8%
Altium Capital Management	0	-465K	EXIT
ARK Investment Management	16.21M	+455.8K	+2.9%
Hood River Capital Management	1.7M	-433.71K	-20.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Grifols SA - ADR - Level III • Terumo

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: absent, affiliate, affix, affixing, bacterium, broaden, Chinese, chose, Colorado, comparison, conferencing, correspondingly, cultural, Delta, endpoint, exfiltrated, foreseeable, guided, III, inflation, inflationary, Noncontrolling, objectionable, Omicron, pendency, post, proportion, remote, resolution, reticence, secret, shortfall, situation, strained, theft, timeframe, unfamiliar, variation, vendor, video, vigilance, Virginia, war

Removed: absence, absenteeism, abundance, acid, acting, Affordable, Aid, amotosalen, anesthesiologist, announcement, Ash, batch, BCT, begun, Biopharma, Bipartisan, breadth, brokerage, Brotech, Canadian, cap, caution, certified, characterized, choice, collecting, compensate, consequential, continual, convince, cooperation, covenant, declared, decree, dedicated, delivered, derivative, detrimental, devalue, diagnostic, diminished, directed, disagree, discontinued, discrepant, distancing, distrust, domiciled, DSMB, dynamic, emerge, Emergency, encouraged, ensuing, entry, epidemic, escalating, ethical, Eurozone, expensed, Favored, finalize, finalized, fine, footprint, formality, Framework, French, front, frozen, globe, guilty, handle, harbor, HHS, horizon, hurricane, ill, importation, improved, inactivating, incidental, infiltrated, influx, inherently, injunction, insolvent, intention, interested, invoicing, jurisdiction, Justice, Kedrion, lawfully, levied, lifting, locally, Louisiana, lowest, mammalian, mature, metric, MINE, minimize, misleading, misstatement, multinational, mutually, Nova, nucleic, occurring, Octapharma, optimized, outbreak, outcome, permitted, pharmacy, Porex, pose, predictive, prepaid, prescribe, prescription, Presently, problem, Producer, Purolite, rapid, reached, reagent, recapture, reconciliation, reconfigured, recordkeeping, refile, reflected, reliable, removal, removing, renew, repeat, responded, resumed, resumption, resurgence, retaliatory, retroactive, reveal, risky, SA, saleable, scheduled, SENIOR, serve, setting, Shield, significance, skill, slowly, social, spike, stage, standardized, stimulate, suitability, suitable, surveillance, Swissmedic, symbol, synthetic, thawing, threaten, threatened, threshold, tie, traceability, Trump, truthful, Turkey, typical, unacceptable, uneven, unprecedented, UNREGISTERED, usability, vaccine, vested, viewed, violate, violating, vote, waived, weaken, Wisconsin, withdrawn, writing

From filing 10-Q 2022 Q1

Financial reports

View all